

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Villoo Morawala PATELL et al.	ATTN: APPLICATION DIVISION
Serial No. 09/868,025	Docket No.: 145865.00005
Filed: October 11, 2000	
For: ISOLATED NUCLEIC ACID SEQUENCE CONFERRING SALT TOLERANCE IN RICE PLANT	

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821 – 1.825

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby state that the information recorded in computer readable form is identical to the substitute paper copy of the Sequence Listing submitted herewith.

I hereby state that the substitute paper copy of the Sequence Listing is supported in the application as filed on October 11, 2000 and that the substitute Sequence Listing does not include new matter.

Respectfully submitted,



Richard Wilder
Reg. No. 31,202

RW/BM/DW/yea
Date: February 19, 2002
Powell, Goldstein, Frazer & Murphy, LLP
P.O. Box 97223
Washington, D.C. 20090-7223

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC10 Rec'd PCT/PTO 19 FEB 2002

In re Patent Application of Villoo Morawala PATELL et al.	ATTN: APPLICATION DIVISION
Serial No. 09/868,025	Docket No.: 145865.00005
Filed: October 11, 2000	
For: ISOLATED NUCLEIC ACID SEQUENCE CONFERRING SALT TOLERANCE IN RICE PLANT	

RESPONSE TO NOTICE OF MISSING REQUIREMENTS

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice of Missing Requirements under 35 U.S.C. 371 mailed
August 17, 2001 (copy enclosed), attached hereto are the following to complete the formal
filing requirements in the above-identified application:

02/22/2002 LILANDRPA 00000010 09260025

01 FC:154

130.00 0P

- ☒ Declaration and Power of Attorney signed by each inventor.
- ☒ Check in the amount of \$130.00 in payment of the declaration surcharge.
- ☒ Preliminary Amendment.
- ☒ Sequence Listing in computer readable format.
- ☒ Sequence Listing (1 paper copy).
- ☒ Statement to Support Filing And Submission in Accordance with 37 C.F.R. §1.821-
1.825.
- ☒ A copy of the Notice of Missing Requirements (Form PCT/DO/EO/905) mailed
August 17, 2001.
- ☒ Petition for Extension of Time (4 months) and check for \$1,440.00.

- ☒ Assignment signed by each inventor.
- ☒ Recordation of Assignment Document form and a check in the amount of \$40.00.
- ☒ Information Disclosure Statement, PTO-1449 and 12 references.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account 50-1682.

Receipt is now awaited by Applicants of the Notification of Acceptance of Application confirming the above-identified filing date and serial number.

Respectfully submitted,



Richard Wilder

Reg. No. 31,202

RW/BM/DW/yea

Date: February 19, 2002

Powell, Goldstein, Frazer & Murphy, LLP
P.O. Box 97223
Washington, D.C. 20090-7223

145805-00005
Missing parts
DUE: 10-17-01



UNITED STATES PATENT AND TRADEMARK OFFICE

REC'D 82101 PGF&M

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/868025	PATELL V	145865.00005
INTERNATIONAL APPLICATION NO.		
PCT/IN00/00099		
I.A. FILING DATE	PRIORITY DATE	
11 OCT 00	13 OCT 99	
DATE MAILED: 17 AUG 2001		

POWELL GOLDSTEIN FRAZER & MURPHY
P O BOX 97223
WASHINGTON, DC 20090 7223

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☒ a Designated Office (37 CFR 1.494) ☐ an Elected Office (37 CFR 1.495):
- ☒ U.S. Basic National Fee. ☐ Indication of Small Entity Status.
 - ☒ Copy of the international application. ☐ Translation of the international application into English.
 - ☐ Oath or Declaration of inventors(s). ☐ Translation of Article 19 amendments into English.
 - ☐ Copy of Article 19 amendments. ☐ Other:
 - ☒ Priority Document.
 - ☒ The International Preliminary Examination Report in English and its Annexes, if any.
 - ☐ Translation of Annexes to the International Preliminary Examination Report into English.
2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- ☐ U.S. Basic National Fee. ☐ Copy of the international application.
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
 - ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
 - ☒ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
 - ☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
4. Additional claim fees of \$_____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/868025	PATELL	V 145865.00005
INTERNATIONAL APPLICATION NO.		
PCT/IN00/00099		
I.A. FILING DATE	PRIORITY DATE	
11 OCT 00	13 OCT 99	

POWELL GOLDSTEIN FRAZER & MURPHY
P O BOX 97223
WASHINGTON, DC 20090 7223

DATE MAILED:

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☒ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

#2/A

1/1/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 2002

#3

In re Patent Application of Villoo Morawala PATELL et al.	
U.S. Patent Application No. 09/868,025	Docket No.: 145865.00005
Filed: October 11, 2000	
For: ISOLATED NUCLEIC ACID SEQUENCE CONFERRING SALT TOLERANCE IN RICE PLANT	


LETTER

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Enclosed please find two communications from the International Bureau of WIPO.
They are the following: PCT Notification of Transmittal of the International Search Report or
the Declaration mailed June 28, 2001 and PCT Notification of the Recording of a Change
mailed August 3, 2001. Examination of these documents is respectfully requested.

Respectfully submitted,



Richard Wilder
Registration No. 31,202
Attorney for Applicant

POWELL, GOLDSTEIN, FRAZER & MURPHY, LLP
P.O. Box 97233
Washington, D.C. 20090-7223
202-347-0066

Date: February 19, 2002
RW/DWW/yea